- Home
- AME vs TAK Comparison
AME vs TAK Comparison
Compare AME & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AME
- TAK
- Stock Information
- Founded
- AME 1930
- TAK 1781
- Country
- AME United States
- TAK Japan
- Employees
- AME N/A
- TAK N/A
- Industry
- AME Industrial Machinery/Components
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- AME Industrials
- TAK Health Care
- Exchange
- AME Nasdaq
- TAK Nasdaq
- Market Cap
- AME 41.8B
- TAK 41.1B
- IPO Year
- AME N/A
- TAK N/A
- Fundamental
- Price
- AME $184.67
- TAK $13.11
- Analyst Decision
- AME Buy
- TAK
- Analyst Count
- AME 8
- TAK 0
- Target Price
- AME $209.00
- TAK N/A
- AVG Volume (30 Days)
- AME 1.1M
- TAK 1.7M
- Earning Date
- AME 02-04-2025
- TAK 01-30-2025
- Dividend Yield
- AME 0.61%
- TAK 4.84%
- EPS Growth
- AME 3.98
- TAK 49.73
- EPS
- AME 5.74
- TAK 1.27
- Revenue
- AME $6,910,463,000.00
- TAK $31,732,209,416.00
- Revenue This Year
- AME $7.44
- TAK $6.15
- Revenue Next Year
- AME $5.77
- TAK $0.86
- P/E Ratio
- AME $32.17
- TAK $20.35
- Revenue Growth
- AME 6.45
- TAK 9.43
- 52 Week Low
- AME $149.03
- TAK $12.58
- 52 Week High
- AME $198.33
- TAK $15.08
- Technical
- Relative Strength Index (RSI)
- AME 56.70
- TAK 45.20
- Support Level
- AME $180.08
- TAK $12.92
- Resistance Level
- AME $181.67
- TAK $13.20
- Average True Range (ATR)
- AME 2.92
- TAK 0.13
- MACD
- AME 0.67
- TAK 0.00
- Stochastic Oscillator
- AME 96.83
- TAK 41.53
About AME AMETEK Inc.
Ametek Inc is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets, and generates major revenue. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. The majority of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.